reports
- Guy Sips
- Kristof Samoy
- Kristof Samoy
CMB.Tech Investment in Chinese ammonia supply
CMB.TECH is investing in the Chinese ammonia supply chain and signed an off-take agreement for green ammonia produced by CEEC in the Jilin Province and will own a minority share in privately owned Andefu, one of China's largest ammonia supply chain companies. While CMB.TECH did not disclose any financials on the deal we estimate linked financials are relatively small. CMB.TECH has a sensible but disciplined investment approach towards decarbonisation. Through the offtake agreement and terminal o...
CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY
CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY Antwerp, Dec. 16, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) is pleased to announce the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and will own a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China's largest ammonia supply chain companies. Green ammonia produced...
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 16 December 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 327,154 of its own shares in the period 8 – 12 December 2025 at an average price of €36.24. The total consideration of this repurchase was €11,855,299. The total number of shares repurchased under this program to date is 2,798,182 shares...
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
- Delphine Brault
- Nathan Mietlicki
- Delphine Brault
- Nathan Mietlicki
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Kristof Samoy
Arcadis 26 year company veteran and GBA-head of Resilience to become n...
Arcadis has nominated Heather Polinsky as its next CEO, effective 1 March 2026, pending shareholder approval at the Annual General Meeting next May. Alan Brookes will step down earlier than expected, as his term was originally set to run until 2027. The leadership change is intended to reinvigorate growth and strengthen the company's market position ahead of its next strategic cycle. Arcadis has missed its organic growth targets from the 2023 CMD, with year-to-date topline growth in 2025 at only...
- Martijn Den Drijver
Arcadis announces Heather Polinsky as new CEO
Arcadis announces Heather Polinsky as new CEO PRESS RELEASE Arcadis announces Heather Polinsky as new CEO Heather Polinsky, 26-year veteran of the company and Global President for Resilience and Mobility, nominated as new Chief Executive Officer (CEO)Alan Brookes to step down as CEO on 1 March 2026 Amsterdam, 11 December 2025 – Arcadis (EURONEXT: ARCAD), the world’s leading company in delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, today announced that the Supervisory Board has nominated Heather Polin...
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 9 December 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 460,622 of its own shares in the period 1 – 5 December 2025 at an average price of €37.42. The total consideration of this repurchase was €17,237,189. The total number of shares repurchased under this program to date is 2,471,028 shares f...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
UCB Detailed results from Fintepla in CDD strengthen epilepsy franchis...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- Martial Descoutures
- Martial Descoutures
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- ING Helpdesk
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.